Approved indications for idelalisib include relapsed chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular B-cell non-Hodgkin lymphoma.
Charles E. Libby, RPh, MS
Advertisement
Articles by Charles E. Libby, RPh, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Modern Therapies Challenge Radiation’s Role in Early Breast Cancer Survival
3
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
4
Gedatolisib Triplet Shows Significant PFS Benefit in HR+/HER2– Breast Cancer
5
